Swiss National Bank
BEAM icon

Swiss National Bank’s Beam Therapeutics BEAM Stock Holding History

Swiss National Bank’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.14M Sell
178,900
-1,700
-0.9% -$51.3K ﹤0.01% 1323
2026
Q1 		$4.3M Buy
180,600
+1,100
+0.6% +$30.5K ﹤0.01% 1449
2025
Q4 		$4.98M Buy
179,500
+4,100
+2% +$105K ﹤0.01% 1355
2025
Q3 		$4.26M Buy
175,400
+2,800
+2% +$55.7K ﹤0.01% 1416
2025
Q2 		$2.94M Hold
172,600
– – ﹤0.01% 1583
2025
Q1 		$3.37M Buy
172,600
+34,800
+25% +$912K ﹤0.01% 1481
2024
Q4 		$3.42M Buy
137,800
+1,100
+0.8% +$28.1K ﹤0.01% 1538
2024
Q3 		$3.35M Hold
136,700
– – ﹤0.01% 1564
2024
Q2 		$3.2M Hold
136,700
– – ﹤0.01% 1550
2024
Q1 		$4.52M Buy
136,700
+4,100
+3% +$128K ﹤0.01% 1360
2023
Q4 		$3.61M Sell
132,600
-9,800
-7% -$243K ﹤0.01% 1489
2023
Q3 		$3.42M Buy
142,400
+16,300
+13% +$437K ﹤0.01% 1514
2023
Q2 		$4.03M Buy
126,100
+4,400
+4% +$143K ﹤0.01% 1439
2023
Q1 		$3.73M Sell
121,700
-14,200
-10% -$560K ﹤0.01% 1440
2022
Q4 		$5.32M Buy
135,900
+2,600
+2% +$116K ﹤0.01% 1278
2022
Q3 		$6.35M Buy
133,300
+4,800
+4% +$274K ﹤0.01% 1136
2022
Q2 		$4.97M Buy
128,500
+47,900
+59% +$1.9M ﹤0.01% 1322
2022
Q1 		$4.62M Buy
80,600
+7,500
+10% +$492K ﹤0.01% 1484
2021
Q4 		$5.83M Buy
73,100
+3,900
+6% +$334K ﹤0.01% 1362
2021
Q3 		$6.02M Buy
69,200
+1,700
+3% +$171K ﹤0.01% 1335
2021
Q2 		$8.69M Buy
67,500
+27,800
+70% +$2.21M 0.01% 1101
2021
Q1 		$3.18M Buy
39,700
+1,400
+4% +$133K ﹤0.01% 1725
2020
Q4 		$3.13M Buy
38,300
+9,700
+34% +$477K ﹤0.01% 1655
2020
Q3 		$704K Hold
28,600
– – ﹤0.01% 2267
2020
Q2 		$801K Buy
+28,600
New +$616K ﹤0.01% 2225

Other funds holding BEAM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $2.17B AUM 134.87% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Swiss National Bank's BEAM Position: Q2 2026 in Review

Swiss National Bank reduced its Beam Therapeutics (BEAM) stake by 0.94% in Q2 2026, selling an estimated $51.3K and leaving 178,900 shares worth $6.14M. The position accounts for ﹤0.01% of the portfolio, ranked #1323.

Swiss National Bank first reported a position in BEAM in Q2 2020 and has held it in 25 quarters since. The position peaked at $8.69M in Q2 2021. 179 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Swiss National Bank held 178,900 shares of Beam Therapeutics worth $6.14M as of Q2 2026.
  • Swiss National Bank sold 1,700 Beam Therapeutics shares in Q2 2026, an estimated $51.3K.
  • Beam Therapeutics made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #1323 holding.
  • Swiss National Bank first reported a position in Beam Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Swiss National Bank's Beam Therapeutics position peaked at $8.69M in Q2 2021.
  • 179 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.